Precision DL

Precision DL is a deep learning software designed to elevate non-ToF PET image quality in F-18 FDG oncology studies, aiming to achieve performance characteristics similar to ToF PET systems. It employs three distinct AI models, trained on varied clinical datasets, to enhance image contrast, reduce noise, and improve quantitative accuracy for images processed on the Omni Legend PET/CT system.

Precision DL is a deep learning-based image processing method developed for enhancing Positron Emission Tomography (PET) images in clinical oncology using F-18 FDG. It is designed to improve the quality of non-Time-of-Flight (non-ToF) PET images acquired with the Omni Legend PET/CT system, making them comparable in quality to images from ToF-capable PET systems. The technology, applicable to patients of all ages, works by enhancing non-ToF Q.Clear images, focusing on improving image Contrast Recovery (CR), Contrast to Noise Ratio (CNR), and quantitation accuracy. Its deep learning algorithms were trained using diverse clinical data from multiple sites to accommodate variations in patient characteristics and imaging protocols. The system features three distinct deep learning models—Low, Medium, and High Precision DL—allowing users to select varying degrees of contrast enhancement versus noise reduction. The High model maximizes contrast enhancement with minimal noise reduction, the Low model provides the opposite, and the Medium model offers an intermediate balance. Non-clinical testing, using both NEMA phantoms and clinical PET-CT exam data independent of the training set, demonstrated improved performance over standard non-ToF Q.Clear reconstruction and comparable performance to hardware-based ToF systems (Discovery MI) in terms of quantitation accuracy, lesion detectability, and potential for dose or scan time reduction. Clinical reader studies with board-certified radiologists further affirmed the acceptable diagnostic quality of Precision DL-processed images.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific deep learning architecture (e.g., CNN, U-Net) is utilized by Precision DL, and what were the key characteristics of the training dataset, such as the number of patients, range of lesion types, and diversity of acquisition protocols?; How does the quantitative accuracy (e.g., SUVmax, SUVmean, metabolic tumor volume) of Precision DL-enhanced non-ToF PET images compare to native hardware-based ToF PET images across different lesion sizes, locations, and uptake intensities?; Are the 'Low, Medium, and High' Precision DL models fixed, or is there a provision for site-specific calibration or fine-tuning based on local scanner performance or radiologist preference for image texture?; What was the specific methodology and quantitative outcome for the 'Dose / Time Reduction' testing mentioned, and how does this practically translate to potential changes in clinical F-18 FDG PET imaging protocols?; Beyond overall image quality, were there any specific oncological scenarios (e.g., detection of small lesions, assessment of treatment response, imaging in challenging patient populations) where Precision DL demonstrated a particularly significant advantage or any identified limitations?